Home / Clinical Decision Support & Reference / Brainomix 360 e-CTA

Brainomix 360 e-CTA

by Brainomix Limited · Based in United Kingdom → — AI-Enabled Precision. We turn ordinary scans into extraordinary insights, enabling precision medicine for better treatment decisions.

Emergency Medicine Neurology Radiology

Website

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Contact vendor

Regulatory Status Disclosed

Overview

Brainomix 360 e-CTA is a key module within the comprehensive Brainomix 360 Stroke imaging solution, designed to provide decision support for acute stroke pathways. This AI-powered tool automates and standardizes the assessment of collaterals on acute stroke patient brain CT Angiography (CTA) scans. Clinicians can utilize e-CTA to estimate the status of collaterals and compute the CTA Collateral Score (CTA-CS). Furthermore, e-CTA provides an indication of the acquisition phase of the CTA scan, aiding in quality control and standardized interpretation. It is specifically designed for use on brain CTA scans of acute ICA or MCA stroke patients and can automatically detect large vessel occlusions (LVOs). The results are integrated into a web browser user interface and can be sent automatically to existing PACS or other radiology systems, with email notifications also available.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

Automated collateral assessment on CTA scans
Computation of CTA Collateral Score (CTA-CS)
Automatic Large Vessel Occlusion (LVO) detection
Indication of CTA acquisition phase for quality control
Multi-planar reconstructions (MPRs) with coronal, sagittal, and axial viewing
Integration within Brainomix 360 Stroke platform
DICOM results sent automatically to PACS or other radiology systems
Email result notifications
Browser-based user interface
Mobile app access to results

Use Cases

Acute stroke pathways decision support
Assessment of collaterals in ICA or MCA stroke patients
Supporting thrombectomy eligibility decisions
Standardizing collateral assessment in stroke imaging
Improving communication and workflow in stroke networks
Quality control of CTA scans

What Physicians Need to Know

Evidence Base

Brainomix 360 e-CTA is part of the Brainomix 360 Stroke platform, which is FDA-cleared and CE-marked. The platform is supported by over 60 peer-reviewed studies published by international academic groups, rigorously tested across diverse clinical settings. e-CTA specifically automates and standardizes the assessment of collaterals on acute stroke patient brain CTA scans and detects large vessel occlusions (LVOs), providing a CTA Collateral Score (CTA-CS) and an indication of the acquisition phase for quality control.

Clinical Validation Studies

A large prospective observational study published in *The Lancet Digital Health* (2025) involving over 450,000 stroke patients across 107 NHS hospitals demonstrated that Brainomix 360 Stroke was associated with a 100% increase in mechanical thrombectomy rates at evaluation sites and improved patient outcomes. A *Frontiers in Neurology* study (2024) showed Brainomix 360 Stroke implementation tripled functional independence rates (16% to 48%) and reduced door-in-door-out (DIDO) times by 61 minutes in a primary stroke center. A real-world evaluation (2023) reported 97.2% successful processing of studies in an average of 4 minutes, with e-CTA achieving 91.5% accuracy for LVO detection. An independent diagnostic accuracy study (2023) found e-CTA had 72% sensitivity, specificity, and diagnostic accuracy for detecting arterial abnormality compared to expert reading. A multi-reader study (2025) indicated e-CTA improved LVO detection sensitivity, specificity, and accuracy for NHS clinicians, increasing confidence and reducing time. However, a real-world service evaluation (2025) noted a positive predictive value (PPV) of 0.5 for e-CTA in LVO detection, with an error rate of 9%, highlighting challenges with anatomical misidentification and LVO in the terminal ICA.

Alert Fatigue Management

The system is designed to alert radiologists and stroke teams about potential LVO patients, aiming to mitigate the risk of patients being overlooked. The Brainomix 360 Stroke Mobile app allows physicians to flag patients eligible for thrombectomy, optimizing workflow and facilitating faster transfer and treatment decisions. Email result notifications are provided, though these are for informational purposes only and not for diagnostic use beyond notification.

Override Rate Data

While the e-ASPECTS module, part of the Brainomix 360 platform, provides an 'automated editable ASPECTS score for clinician review', specific override rate data for Brainomix 360 e-CTA is not explicitly provided in the available literature.

Differential Diagnosis Support

Brainomix 360 e-CTA primarily focuses on identifying large vessel occlusions and assessing collateral circulation in acute ischemic stroke. It aids in differentiating between ischemic and hemorrhagic stroke by detecting hyperdense volumes (indicating bleeding) via e-ASPECTS, and helps guide treatment decisions based on imaging findings like infarct volume and tissue at risk.

Clinical Workflow Integration

Brainomix 360 e-CTA offers seamless integration with existing PACS and other radiology systems, with DICOM results automatically sent. It features an integrated web browser user interface and a mobile app (iOS and Android) for secure access, review, and sharing of images and patient data across stroke networks. The tool provides advanced CTA multi-planar reconstructions (MPRs) to support interventional planning. This integration is designed to optimize workflow, reduce door-in-door-out (DIDO) times, and improve communication for faster treatment and transfer decisions.

Decision Audit Trail

Information regarding a specific 'decision audit trail' feature for Brainomix 360 e-CTA is not explicitly available in the provided search results.

Physician Tip

Brainomix 360 e-CTA is a powerful adjunct for acute stroke assessment, but it should be used in conjunction with expert clinical and radiological interpretation, not as a standalone diagnostic tool. Be aware of potential limitations, such as the reported PPV in real-world settings and challenges with anatomical misidentification or LVOs in the terminal ICA. Always view non-compressed images on a diagnostic viewer for definitive diagnostic decisions, as mobile previews are for informational purposes only. The tool is particularly beneficial for standardizing assessment, speeding up decision-making, and improving communication across stroke networks, especially for non-stroke specialists.

Brainomix 360 e-CTA is DICOM compliant and integrates seamlessly with existing PACS and other radiology systems. It operates via a cloud-based platform and a dedicated mobile application (iOS and Android). Brainomix also engages in strategic partnerships with various medical imaging platforms, clinical workflow solutions, pharmaceutical companies, cloud service providers, and medical imaging equipment manufacturers, facilitating broader integration and collaborative efforts in clinical trials.

At a glance

Pricing Contact vendor

Deployment Cloud Service (EU And US) And On Site Server Within The Hospital Network.

Visit site

Details

Category	Clinical Decision Support & Reference, Neurology AI, Radiology & Imaging AI
Pricing	Contact vendor Contact vendor for licensing options; individual modules can be licensed separately or as part of a package
Deployment	Cloud service (EU and US) and on-site server within the hospital network.
Compliance
BAA Available	Unknown AI-estimated
HIPAA Compliant	Unknown AI-estimated
FDA Status	1 AI-estimated Brainomix 360 e-CTA is part of the Brainomix 360 Stroke solution, which has received FDA clearance. It is a computer-aided diagnosis (CADx) software device intended to assist clinicians in the assessment of collaterals and detection of large vessel occlusions on CT angiography scans for acute stroke patients.
Integrations
EHR	Not specified
Specialties	Emergency Medicine, Neurology, Radiology

What the Web Says

Brainomix 360 e-CTA is an AI-powered decision support software designed to assist physicians in the rapid and reliable analysis of CT angiography (CTA) images for acute stroke patients. It aims to standardize the assessment of collateral circulation and automatically detect large vessel occlusions (LVOs), ultimately facilitating faster treatment decisions and improving patient outcomes. The platform is part of the broader Brainomix 360 Stroke suite, which has shown to increase mechanical thrombectomy rates and functional independence in stroke patients.

Overall: Positive

Strengths

Rapid and reliable analysis of CT imaging in acute stroke settings, with an average processing time of 4 minutes.
Standardizes the assessment of collaterals and automatically detects Large Vessel Occlusions (LVOs) in CTA scans.
Improves confidence in treatment decisions and speeds up patient triaging, especially for non-stroke specialists.
Associated with a significant increase in mechanical thrombectomy rates and improved functional independence for stroke patients.
Offers advanced CTA multi-planar reconstructions (MPRs) for interventional planning.
Accessible via a mobile app, allowing physicians to securely access, review, and share images and patient data across a network.

Limitations

Lower accuracy for identifying hyperdense thrombus due to false positives.
Poor positive predictive value (PPV) for e-CTA in real-world NHS settings, with an error rate of 9%.
Common AI errors include anatomical misidentification, presence of other pathology, and misidentifying LVO in the terminal internal carotid artery (ICA).
Should be used as an adjunct to expert interpretation rather than a standalone decision-making tool.
Some studies suggest the clinical utility may be overstated in real-world use where LVO prevalence is low.

Based on reviews from: Brainomix 360 | AI-Enabled Decision Support for Stroke Assessment, Real-world evaluation of Brainomix 360 software, Brainomix 360 The Most Comprehensive Stroke Imaging Solution - Catalogs Medicalexpo, Brainomix, Real world clinical experience of using Brainomix e-CTA software in a medium size acute National Health Service Trust - PubMed, e-CTA - Brainomix - Health AI Register, Transforming Stroke Diagnosis with Artificial Intelligence: A Scoping Review of Brainomix e-Stroke, Aidoc, RapidAI, and Viz.ai - MDPI, FDA nod broadens use of Brainomix's stroke AI - pharmaphorum, Brainomix 360 e-Lung Technology speeds up PPF detection, Brainomix 360 Stroke - Blackford Analysis, Brainomix Advances Stroke Care with Landmark FDA Clearance, Revolutionizing Acute Stroke Care: A Review of Food and Drug Administration-Approved Software as Medical Devices for Stroke Triage - Brainomix, Real-world evaluation of Brainomix e-Stroke software - PMC, Abstract TP86: Evaluating the Implementation of Brainomix 360 AI Stroke Software in a Robust Academic Hub-and-Spoke Telestroke Network, Real-world evaluation of Brainomix e-Stroke software - PubMed, Thoughts on RAPID Reader / Brainomix ASPECTS for stroke imaging. : r/Radiology - Reddit, Brainomix Stroke AI Software Hailed as u1ffeRevolutionary,' Helping More Patients Fully Recover - PR Newswire, Triage Stroke - Brainomix, Brainomix 360 Stroke: The Most Advanced and Clinically Validated AI Stroke Solution, Study Shows How AI is Transforming Stroke Care - Diagnostic and Interventional Cardiology

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Brainomix 360 e-CTA

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

Press & Coverage

X-ray Interpreter

Brainomix 360 e-CTA | FDA Radiology AI Device - X-ray Interpreter

Brainomix 360 e-CTA is a software system utilized by trained medical professionals for analyzing CT Angiography images of the brain. It processes these images to aid in the assessment of stroke patients.

2025-01

accessdata.fda.gov

Re - accessdata.fda.gov

This FDA document details the Brainomix 360 e-CTA as an image processing software package for trained professionals to view, process, and analyze CTA imaging datasets, compliant with 21 CFR, Part 820.30 requirements and ISO 14971:2019 for risk management.

2025-01

British Journal of Radiology

Artificial intelligence in neuroradiology: a review of Food and Drug Administration-regulated algorithms | British Journal of Radiology | Oxford Academic

This review article discusses FDA-cleared AI algorithms in neuroradiology, listing Brainomix 360 e-CTA as a Medical Image Management and Processing System (MIMPS) for detecting Large Vessel Occlusion (LVO) and providing collateral scoring on CTA, cleared on January 6, 2025.

2026-05

PMC (PubMed Central)

Artificial intelligence assisted detection of large vessel occlusion on CT angiography in acute stroke patients: a multi-reader multi-case study - PMC

This study assessed the impact of Brainomix 360 e-CTA software on clinical decision-making in acute ischemic stroke patients, demonstrating improved sensitivity, specificity, and accuracy of LVO detection, along with increased confidence and reduced time for interpretation among NHS clinicians.

2025-02

accessdata.fda.gov

August 26, 2025 Brainomix Limited Delanyo Mensah Regulatory Affairs Specialist First Floor, Seacourt Tower West Way Oxford, OX2 - accessdata.fda.gov

An FDA filing from August 2025 lists Brainomix 360 e-CTA (K242123) among other Brainomix 360 products, indicating ongoing regulatory activities and updates for their suite of AI-powered stroke solutions.

2025-08

accessdata.fda.gov

February 14, 2025 Brainomix Limited Delanyo Mensah Regulatory Affairs Specialist First Floor, Seacourt Tower West Way Oxford, OX - accessdata.fda.gov

This FDA document from February 2025 references Brainomix 360 e-CTA (K192692) in the context of Brainomix 360 e-ASPECTS, highlighting the company's portfolio of AI-driven tools for stroke assessment.

2025-02

PMC (PubMed Central)

Prospective Evaluation of Artificial Intelligence Imaging Support Software for Acute Ischemic Stroke in the Mayo Clinic Telestroke Network - PMC

A prospective evaluation in the Mayo Clinic Telestroke Network assessed the real-world impact of Brainomix 360 Stroke software, including e-CTA, on acute ischemic stroke treatment rates and times, with clinicians reporting positive changes and increased trust in the software's accuracy.

2025-05

Innolitics

Brainomix 360 e-CTA (K192692) u2014 FDA 510(k) | Innolitics

Innolitics lists the FDA 510(k) clearance for Brainomix 360 e-CTA (K192692) on May 28, 2020, and a subsequent clearance (K242123) on January 6, 2025, indicating its regulatory approval as a radiology device.

2020-05

Videos

Product demos, reviews, and walkthroughs for Brainomix 360 e-CTA.

Loading videos...

View all on YouTube

Frequently Asked Questions

How does Brainomix 360 e-CTA utilize AI to assist in acute stroke diagnosis and treatment decisions?

Brainomix 360 e-CTA employs AI algorithms to automate and standardize the assessment of collaterals on acute stroke patient brain CT angiography (CTA) scans. It automatically detects large vessel occlusions (LVOs) and calculates a CTA Collateral Score (CTA-CS), providing physicians with real-time, objective insights to support faster and more confident treatment and transfer decisions. This AI-powered analysis aims to streamline the stroke pathway and improve patient outcomes.

What regulatory approvals does Brainomix 360 e-CTA have, and what are the implications for its clinical use?

Brainomix 360 e-CTA is part of the Brainomix 360 Stroke platform, which is FDA-cleared in the US and CE-marked in Europe. These regulatory approvals signify that the software has met specific safety and performance standards, allowing its use as a decision support tool in clinical practice for acute ischemic stroke patients.

What are the main alternatives to Brainomix 360 e-CTA in the healthcare AI stroke imaging market, and how do they compare?

Key alternatives in the AI stroke imaging market include RapidAI, Viz.ai, and Aidoc. While all aim to optimize stroke workflows, Brainomix 360 e-CTA has demonstrated high diagnostic accuracy for automated LVO detection, performing comparably to or, in some studies, outperforming RapidAI for LVO detection and ASPECTS agreement. Each platform may have different strengths, such as RapidAI's focus on perfusion or Viz.ai's reported reductions in door-to-puncture times.

How is Brainomix 360 e-CTA typically priced, and what factors influence the cost for a healthcare institution?

Specific pricing for Brainomix 360 e-CTA is generally not publicly disclosed and is typically negotiated directly with the vendor. The cost can be influenced by factors such as the licensing model (e.g., individual modules or a complete package), the size and volume of the healthcare institution, and the scope of integration within existing PACS or other radiology systems.

What are the known limitations or potential pitfalls of relying on Brainomix 360 e-CTA for stroke imaging interpretation?

While highly beneficial, Brainomix 360 e-CTA is a decision support tool and not intended for primary image interpretation. Its diagnostic accuracy can be influenced by local factors like scanner type and CT protocols, and some studies have noted potential errors due to anatomical misidentification, other pathologies, or misidentifying LVO in the terminal ICA. It is specifically designed for acute ICA or MCA stroke patients and assesses collaterals in the MCA territory.

How does Brainomix 360 e-CTA integrate into existing stroke care workflows and imaging systems?

Brainomix 360 e-CTA is designed to integrate seamlessly into clinical pathways, with results accessible via email, DICOM, or a web browser interface. It connects with DICOM-compliant devices, such as PACS, to transfer scans for processing and can send automated notifications. This integration aims to optimize workflow, facilitate faster transfer, and improve communication across stroke networks.

What is the diagnostic accuracy of Brainomix 360 e-CTA, and how has it been validated?

Studies have shown that Brainomix 360 e-CTA has a diagnostic accuracy for detecting arterial abnormality ranging from 72-76% compared to expert interpretation. For large vessel occlusions, its accuracy has been reported at 91.5% in a real-world evaluation, with sensitivity and specificity for LVO detection comparable to less experienced physicians and similar to experienced physicians for proximal LVOs. Validation often involves large-scale independent testing against masked expert readings and real-world observational studies.

Compare Brainomix 360 e-CTA

Brainomix 360 e-CTA vs Chest-CAD

Clinical Decision Support & Reference Adjacent · 60/100

Both Brainomix 360 e-CTA and Chest-CAD are AI-powered clinical decision support tools for radiology, holding FDA clearance and aiming to improve diagnostic accuracy and workflow efficiency. However, they…

Brainomix 360 e-CTA vs PeraServer and PeraTrend

Clinical Decision Support & Reference Adjacent · 60/100

Brainomix 360 e-CTA is an AI tool specifically designed for acute stroke patients, focusing on image analysis of CT angiography scans to detect large vessel occlusions and assess…

Brainomix 360 e-CTA vs Google Med-PaLM 2

Clinical Decision Support & Reference Adjacent · 60/100

Brainomix 360 e-CTA is a specialized AI tool for acute stroke imaging analysis, focusing on automated detection and assessment of large vessel occlusions and collaterals on CT angiography…

Brainomix 360 e-CTA vs Google Cloud AI (with BAA)

Clinical Decision Support & Reference Adjacent · 65/100

Brainomix 360 e-CTA is a specialized AI tool focused on acute stroke diagnosis from CT angiography scans, offering automated collateral assessment and large vessel occlusion detection. Google Cloud…